Analyses / Impact Analysis / 119 · SJRES 84 Impact Analysis

119-SJRES-84 Investigative Journalist Impact Analysis

119 · SJRES 84 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services relating to "Patient Protection and Affordable Care Act; Marketplace Integrity and Affordability".

health_and_safety Health
This joint resolution nullifies the rule titled Patient Protection and Affordable Care Act; Marketplace Integrity and Affordability, which was issued by the Centers for Medicare & Medicaid...
Bottom-line assessment
Overall stance: Neutral. Disapproval would likely preserve coverage access for low‑income, DACA, and transgender populations (and avoid higher 2026 OOP caps), while sacrificing the rule’s projected APTC savings and delaying or constraining federal tools aimed at curbing improper enrollments. Given conflicting evidence on premiums and risk selection, and the CRA’s long‑run path‑dependence, the balance of impacts is mixed and context‑dependent. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…[5]KFF — KFF – New Rule Proposes Changes to ACA Coverage of Gender‑Affirming Care…[2]Legal Information Institute — 5 U.S.C. § 801 – Congressional review (LII)
CMS‑projected 2026 enrollment change under the rule
725000to 1,800,000 fewer enrollees
2026 OOP maximum (self‑only) in the rule
10600USD
2025 OOP maximum (self‑only) baseline
9200USD
Illustrative APTC reduction examples in 2026 (select provisions)
1414USD millions
Published
11 Dec 2025
Updated
11 Dec 2025
Tags
Impact Analysis · Congressional Review Act · ACA Marketplaces
Unvetted
01 · Section

Summary

What changes if S.J.Res. 84 passes? The 2025 CMS rule would be void and treated as if it never took effect, and CMS could not reissue a “substantially the same” rule absent new statutory authorization. Practically, Marketplace operations would continue under pre‑rule policies for 2026, while litigation over the 2025 rule’s provisions would become moot. [2]Legal Information Institute — 5 U.S.C. § 801 – Congressional review (LII)

  • Enrollment: Disapproval avoids the rule’s own projected 725,000–1,800,000 drop in average 2026 Marketplace enrollment tied to its verification, SEP, and parameter changes. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Subsidies and costs: It forgoes targeted APTC savings the rule attributed to stricter eligibility/verification (hundreds of millions in 2026 across several provisions), and keeps 2026 cost‑sharing parameters on the previously published track. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Eligibility: DACA recipients remain eligible for Marketplace/BHP coverage under the 2024 rule (subject to existing court orders), rather than being excluded by the 2025 rule. [4]CMS — CMS – Final Rule Clarifying Eligibility of DACA Recipients and Certain Ot…[1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Benefits: It prevents the rule’s prohibition on treating specified sex‑trait modification procedures as an Essential Health Benefit—maintaining current state and issuer discretion with EHB protections. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…[5]KFF — KFF – New Rule Proposes Changes to ACA Coverage of Gender‑Affirming Care…
  • Process integrity: New measures (e.g., pre‑enrollment SEP verification targets, $5 auto‑renew premium, broker enforcement standard) would not take effect—leaving CMS with existing tools and state oversight to address improper enrollments. [6]CMS — CMS Fact Sheet: 2025 Marketplace Integrity and Affordability Final Rule[1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
02 · Section

Economic Effects

Key market, budget, and operational impacts if the rule is disapproved.

  • Federal outlays (APTC): CMS’s RIA attributed specific APTC reductions to the rule’s verification policies (e.g., roughly $191M and $957M in 2026 from income‑inconsistency and tax‑filing provisions, plus about $266M via documentation‑timing effects) and about $34M/year from excluding DACA recipients—savings that would not occur if the rule is overturned. Figures are illustrative and time‑bound; CMS noted uncertainties and possible Medicaid cost shifts. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Premiums and risk pool: CMS argued the rule would reduce adverse selection and stabilize premiums; independent analyses warn pre‑enrollment verification can deter eligible, healthier enrollees and worsen the risk pool. Disapproval preserves broader access but may leave improper enrollment risks unaddressed—net premium effects are ambiguous. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…[7]Brookings Institution — Brookings – SEP pre‑enrollment verification could backf…
  • Consumer cost‑sharing: The rule’s premium‑adjustment methodology would have raised the 2026 maximum annual OOP to $10,600 (self‑only), above both 2025 levels and previously published 2026 parameters; disapproval retains the prior methodology/levels. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Operational costs: States/insurers avoid near‑term IT and administrative changes for paused SEPs, OEP dates, and verification targets; however, they also lose federal anti‑fraud levers that could reduce churn and unauthorized enrollments. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Market signaling and litigation risk: Conflicting district‑court rulings created uncertainty in 2025; CRA disapproval would remove that rule‑specific uncertainty, though plan pricing for 2026 may already reflect expectations of a smaller/sicker pool. [8]Reuters — Reuters – U.S. judge pauses changes to federal health insurance marke…[9]Reuters — Reuters – Democratic AGs lose bid to halt ACA marketplace changes (Oc…
CMS‑projected 2026 enrollment change under the rule
725000to 1,800,000 fewer enrollees
2026 OOP maximum (self‑only) in the rule
10600USD
2025 OOP maximum (self‑only) baseline
9200USD
Illustrative APTC reduction examples in 2026 (select provisions)
1414USD millions
DACA effect estimated by CMS (QHP enrollment)
10000fewer enrollees/year
03 · Section

Social Effects

Distributional consequences for consumers and communities.

  • Low‑income enrollees: Retaining the 150% FPL monthly SEP during 2026 maintains a continuous pathway to coverage for people cycling income and those leaving Medicaid, mitigating churn and administrative barriers highlighted by commenters; CMS contended this SEP enabled improper enrollments. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • DACA recipients: Disapproval preserves access to subsidized Marketplace/BHP coverage authorized in 2024 (effective Nov 1, 2024), reducing uninsured rates among DACA‑eligible populations where not enjoined. [4]CMS — CMS – Final Rule Clarifying Eligibility of DACA Recipients and Certain Ot…
  • Transgender individuals: Preventing the rule’s EHB exclusion averts potential loss of cost‑sharing protections and benefit certainty for gender‑affirming care; state benchmarking diversity remains. [5]KFF — KFF – New Rule Proposes Changes to ACA Coverage of Gender‑Affirming Care…
  • Consumers targeted by improper enrollments: Without the rule’s new $5 auto‑renew bill and verification expansions, some tools intended to curb unauthorized enrollments would not deploy; enforcement reverts to pre‑rule mechanisms. [6]CMS — CMS Fact Sheet: 2025 Marketplace Integrity and Affordability Final Rule
  • Scale context: Marketplace selections reached about 21.3 million for 2024, underscoring potential population‑level significance of changes to eligibility and SEPs. [10]CMS — CMS – Marketplace 2024 Open Enrollment Period Report: Final National Snap…
04 · Section

Environmental Effects

Direct environmental impacts are minimal; any effects are indirect via utilization.

  • Healthcare’s footprint: U.S. health care accounts for ~8.5% of national GHG emissions. Higher coverage can marginally raise utilization‑related emissions; the direction/size depends on substitution (e.g., preventive vs. acute care) and delivery models (e.g., telehealth). The resolution does not regulate environmental performance. [11]Commonwealth Fund — Commonwealth Fund – How the U.S. Health Care System Contrib…
  • Net effect: Disapproval that preserves coverage access likely has negligible system‑wide emissions impact compared with broader sector drivers (hospital energy, supply chains). [11]Commonwealth Fund — Commonwealth Fund – How the U.S. Health Care System Contrib…
05 · Section

Temporal Analysis

Short‑term stabilization vs. long‑term policy path dependence.

  • Immediate (2026 plan year): Continuity of 2024 policies reduces disruption during subsidy transitions and Medicaid unwinding tail effects; it also leaves in place conditions CMS linked to improper enrollments, pending alternative oversight. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Medium term (2027+): Without the rule, the federal OEP remains on the prior calendar unless separately changed; the rule’s temporary verification sunrises/expirations become moot. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Long term: CRA disapproval bars “substantially the same” rulemaking indefinitely, limiting CMS’s ability to re‑adopt similar anti‑fraud mechanisms even if evidence later supports narrower versions—unless Congress authorizes them. [2]Legal Information Institute — 5 U.S.C. § 801 – Congressional review (LII)[3]Congressional Research Service — The Congressional Review Act (CRA): Frequently…
06 · Section

Unintended Consequences

Risks and second‑order effects identified in credible sources.

  • Program integrity: Disapproval could prolong vulnerabilities to unauthorized enrollments and agent/broker abuses identified by CMS, shifting oversight burden to state regulators and post‑hoc enforcement. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  • Coverage disruptions if rule stands vs. is voided: 2025 litigation produced mixed preliminary outcomes in different courts; CRA disapproval would end rule‑specific uncertainty but at the cost of losing intended integrity measures. [8]Reuters — Reuters – U.S. judge pauses changes to federal health insurance marke…[9]Reuters — Reuters – Democratic AGs lose bid to halt ACA marketplace changes (Oc…
07 · Section

Assessment

Overall stance: Neutral. Disapproval would likely preserve coverage access for low‑income, DACA, and transgender populations (and avoid higher 2026 OOP caps), while sacrificing the rule’s projected APTC savings and delaying or constraining federal tools aimed at curbing improper enrollments. Given conflicting evidence on premiums and risk selection, and the CRA’s long‑run path‑dependence, the balance of impacts is mixed and context‑dependent. [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…[5]KFF — KFF – New Rule Proposes Changes to ACA Coverage of Gender‑Affirming Care…[2]Legal Information Institute — 5 U.S.C. § 801 – Congressional review (LII)

08 · Section

Sourcing

Primary documents and independent reporting relied upon.

  1. Federal Register final rule, June 25, 2025 (90 FR 27074–27224). [1]Federal Register / GPO — Federal Register – Patient Protection and Affordable C…
  2. CMS fact sheet on the 2025 final rule. [6]CMS — CMS Fact Sheet: 2025 Marketplace Integrity and Affordability Final Rule
  3. GAO major‑rule report noting publication and effective dates and summary impacts. [13]U.S. Government Accountability Office — GAO – Report under 5 U.S.C. §801 on HHS…
  4. CRA statutory effects and FAQs (LII; CRS). [2]Legal Information Institute — 5 U.S.C. § 801 – Congressional review (LII)[3]Congressional Research Service — The Congressional Review Act (CRA): Frequently…
  5. Litigation coverage (Reuters). [8]Reuters — Reuters – U.S. judge pauses changes to federal health insurance marke…[9]Reuters — Reuters – Democratic AGs lose bid to halt ACA marketplace changes (Oc…
  6. 2024 Marketplace enrollment baseline (CMS). [10]CMS — CMS – Marketplace 2024 Open Enrollment Period Report: Final National Snap…
  7. DACA eligibility rule (CMS 2024). [4]CMS — CMS – Final Rule Clarifying Eligibility of DACA Recipients and Certain Ot…
  8. Gender‑affirming care/EHB analysis (KFF). [5]KFF — KFF – New Rule Proposes Changes to ACA Coverage of Gender‑Affirming Care…
  9. SEP verification research commentary (Brookings). [7]Brookings Institution — Brookings – SEP pre‑enrollment verification could backf…
  10. Health‑sector emissions context (Commonwealth Fund). [11]Commonwealth Fund — Commonwealth Fund – How the U.S. Health Care System Contrib…
Sources cited
  1. [1] Federal Register – Patient Protection and Affordable Care Act; Marketplace Integrity and Affordability (Final Rule) Federal Register / GPO
  2. [2] 5 U.S.C. § 801 – Congressional review (LII) Legal Information Institute
  3. [3] The Congressional Review Act (CRA): Frequently Asked Questions (CRS) Congressional Research Service
  4. [4] CMS – Final Rule Clarifying Eligibility of DACA Recipients and Certain Other Noncitizens (May 3, 2024) CMS
  5. [5] KFF – New Rule Proposes Changes to ACA Coverage of Gender‑Affirming Care (and update on final) KFF
  6. [6] CMS Fact Sheet: 2025 Marketplace Integrity and Affordability Final Rule CMS
  7. [7] Brookings – SEP pre‑enrollment verification could backfire Brookings Institution
  8. [8] Reuters – U.S. judge pauses changes to federal health insurance marketplace (Aug. 22, 2025) Reuters
  9. [9] Reuters – Democratic AGs lose bid to halt ACA marketplace changes (Oct. 2, 2025) Reuters
  10. [10] CMS – Marketplace 2024 Open Enrollment Period Report: Final National Snapshot CMS
  11. [11] Commonwealth Fund – How the U.S. Health Care System Contributes to Climate Change Commonwealth Fund
  12. [12] Web search · turn 5 #8
  13. [13] GAO – Report under 5 U.S.C. §801 on HHS “Marketplace Integrity and Affordability” U.S. Government Accountability Office

Discussion